Should patients with hepatitis C genotype 2/3 infection who are slow responders to pegylated interferon/ribavirin have treatment duration extended?
Carla Silva, Elizabeth Ianna, Tracey Jones, Joshua Davis
Research output: Contribution to journal › Comment/debate